Impotence of organic origin
ICD-10 N48.4 · ICD-11 HA01.1Z

What is the first-line treatment of impotence of organic origin?

Impotence of organic origin is erectile dysfunction arising from a physiological cause. First-line management follows a structured protocol with a defined clinical goal and a preferred pharmacological approach.

Clinical goal

Achieve a penile erection sufficient for satisfactory sexual performance.

Treatment approach — partial overview

First-line therapy centres on an oral phosphodiesterase type 5 inhibitor, with dosing titrated to achieve optimal efficacy — provided no contraindications apply. Multiple FDA-approved agents within this class are available.

Agent selection, titration guidance, and contraindication checks are detailed in the full protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1016/j.juro.2018.05.004

Men with ED should be informed regarding the treatment option of an FDA-approved oral phosphodiesterase type 5 inhibitor (PDE5i), including discussion of benefits and risks/burdens, unless contraindicated.

For men who are prescribed PDE5i, the dose should be titrated to provide optimal efficacy.

The FDA-approved oral phosphodiesterase type 5 inhibitors (PDE5i) available for management of ED in the U.S. include sildenafil, tadalafil, vardenafil, and avanafil.

View source ↗